化疗药物敏感试验在肝细胞癌患者化疗中的应用

聂磊; 吴东德; 张峰; 夏晓勤

doi:10.3969/j.issn.1001-5256.2013.08.016

化疗药物敏感试验在肝细胞癌患者化疗中的应用

DOI: 10.3969/j.issn.1001-5256.2013.08.016

湖北省肿瘤医院肝胆胰科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 218
- HTML全文浏览量: 16
- PDF下载量: 107
- 被引次数: 0
出版历程
- 收稿日期: 2012-10-17
- 出版日期: 2013-08-20

Application of chemosensitivity test in regional chemotherapy for hepatocellular carcinoma via hepatic artery and portal vein

摘要

摘要:
目的采用四甲基偶氮唑盐（MTT）法检测不同化疗药物对肝细胞癌（HCC）的敏感性来指导肝动脉和门静脉区域化疗的个体化化疗方案。方法选取我院2008年12月至2011年12月收治的不能手术切除的42例HCC患者肝癌样本,采用原代肝癌细胞培养联合MTT法检测5-氟尿嘧啶、顺铂、丝裂霉素、阿霉素、羟基喜树碱、吉西他滨、奥沙利铂7种常用化疗药物的敏感性,并根据药敏实验选择个体化化疗方案,指导其中24例患者接受肝动脉和门静脉区域化疗,与传统肝动脉灌注化疗（TAI）治疗的20例患者对比观察疗效。敏感率的比较采用卡方检验,至疾病进展时间（TTP）的比较采用秩和检验。结果肝癌对药物敏感率依次为奥沙利铂64.3%、羟基喜树碱45.2%、顺铂40.5%、吉西他滨38.1%、阿霉素33.3%、5-氟尿嘧啶21.4%、丝裂霉素16.7%。根据药敏实验选择个体化化疗方案的药敏组出现治疗敏感的符合率为70.8%,并与对照组相比在客观缓解率（50.0%vs 20.0%,P=0.039）、疾病控制率（70.8%vs 35.0%,P=0.017）及TTP[（4.7±2.9）m vs（2.6±1.3）m,P=0.032]方...
- 癌,肝细胞 /
- 药物筛选试验,抗肿瘤 /
- 化学疗法,肿瘤,局部灌注
Abstract:
Objective To evaluate the chemosensitivities of hepatocellular carcinoma (HCC) to different chemotherapy drugs by 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyl-2H tetrazolium bromide (MTT) assay and to provide guidance for individualized chemotherapy regimen in regional chemotherapy via the hepatic artery and portal vein.Methods Forty-two HCC samples were selected.Primary culture of HCC cells combined with MTT assay were used to evaluate the chemosensitivities of HCC to 5-fluorouracil (5-FU) , cisplatin (DDP) , mitomycin C (MMC) , adriamycin (ADM) , hydroxycamptothecine (HCPT) , gemcitabine (Gemzar) , and oxaliplatin (OXA) .Individualized chemotherapy regimens were developed according to the chemosensitivity test results to guide regional chemotherapy via the hepatic artery and portal vein in 24 of these patients (as an individualized chemotherapy group) .The therapeutic efficacy was compared with that of transcatheter arterial infusion performed in 20 patients (as a control group) .The chi-square test was used for comparison of sensitivity rate, and the rank-sum test was used for comparison of time to progression (TTP) .Results The sensitivity rates of HCC were 64.3% to OXA, 45.2% to HCPT, 40.5% to DDP, 38.1% to Gemzar, 33.3% to ADM, 21.4% to 5-FU, and 16.7% to MMC.Compared with the control group, the individualized chemotherapy group had a significantly higher objective response rate (50.0% vs 20.0%, P= 0.039) , a significantly higher disease control rate (70.8% vs 35.0%, P = 0.017) , and a significantly longer TTP ( (4.7±2.9) m vs (2.6±1.3) m, P = 0.032) .Conclusion In vitro chemosensitivity test based on MTT assay may be used to screen out the chemotherapy drugs in individualized chemotherapy for HCC and provide guidance for regional chemotherapy via the hepatic artery and portal vein, so as to improve the effect of chemotherapy.
- carcinoma /
- hepatocellular /
- drug screening assays

HTML全文

参考文献(10)

[1]YAN F.Clinical efficacy of double-intervention treatment of ad-vanced liver cancer[J].J Clin Exp Med, 2011, 10 (16) :1282-1283. (in Chinese) 严峰, 双介入治疗中晚期肝癌的临床效果观察[J].临床和实验医学杂志, 2011, 10 (16) :1282-1283.

[2]LI HP, TAO JS, GAO B, et al.The expression and clinical signifi-cance of resistance gene in hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (9) :972-975. (in Chinese) 李海平, 陶建蜀, 高波, 等.肝细胞癌中耐药基因的表达及意义[J].临床肝胆病杂志, 2011, 27 (9) :972-975.

[3]UEDA H, FUKUCHI H, TANAKA C.Toxicity and efficacy of he-patic arterial infusion chemotherapy for advanced hepatocellular car-cinoma[J].Oncol Lett, 2012, 3 (2) :259-263.

[4]MAEJIMA K, TOKUNAGA A, KIYAMA T, et al.Chemosensitivity test for5-fluorouracil and5-chloro-2, 4-dihydroxypyridine pre-dicts outcome of gastric cancer patients receiving S-1postoperatively[J].Gastric Cancer, 2010, 13 (4) :231-237.

[5]WU B, ZHU JS, ZHANG Y, et al.Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer:One institu-tion's experience[J].World J Gastroenterol, 2008, 14 (19) :3064-3068.

[6]TANG DP, ZHANG CQ, TANG K, et al.Serial chemosensitivity test for liver cancer chemotherapy[J].Chin J Oncol Prev Treat, 2009, 1 (1) :18-20, 23. (in Chinese) 唐东平, 张翠卿, 唐凯, 等.系列化疗药敏或耐药试验在肝癌化疗中的应用研究[J].中国癌症防治杂志, 2009, 1 (1) :18-20, 23.

[7]SARGENT JM.The use of the MTT assay to study drug resistance in fresh tumour samples[J].Recent Results Cancer Res, 2003, 16 (1) :13-25.

[8]BURSTEIN HJ, MANGU PB, SOMERFIELD MR, et al.American So-ciety of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays[J].J Clin Oncol, 2011, 29 (24) :3328-3330.

[9]CHEN W, DENG J, YANG XJ, et al.The levels of TNF-α, sIL-2R and VEGF in patients with primary hepatic carcinoma after double intra-arterial infusion of anti-cancerous agents[J].J Clin Hepatol, 2010, 26 (2) :203-204, 209. (in Chinese) 陈卫, 邓俊, 杨小娟, 等.肝癌双灌注介入治疗后血清TNF-α、sIL-2R以及VEGF水平的变化与预后相关[J].临床肝胆病杂志, 2010, 26 (2) :203-204, 209.

[10]ZHENG JL, LIANG LJ, HU WJ, et al.Distribution of5-FU in rat plasma and liver tissue after local5-FU infusion[J].J South-ern Med Univ, 2008, 28 (5) :823-827. (in Chinese) 郑惊雷, 梁力建, 胡文杰, 等.区域性灌注化疗时5-FU的血液和肝脏组织药物浓度分布特征[J].南方医科大学学报, 2008, 28 (5) :823-827.

施引文献

资源附件(0)

访问统计